MarketCap
Facebook
X
Telegram
AxoGen EBITDA | AXGN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA AxoGen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.19 M | 3.18 M | -17.2 M | -26.9 M | -22.7 M | -21.7 M | -28.5 M | -19.6 M | -7.38 M | -7.69 M | -9.02 M | -9.6 M | -9.45 M | -7.49 M | -6.63 M | -4.18 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.18 M | -28.5 M | -12.3 M |
Quarterly EBITDA AxoGen
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.06 M | -1.23 M | - | 6.94 M | 3.33 M | 67 K | - | 1.34 M | 1.23 M | -3.04 M | - | -2.87 M | -6.1 M | -6.63 M | - | -4.09 M | -7.21 M | -10.6 M | - | -4.63 M | -6.52 M | -5.45 M | - | -671 K | -7.94 M | -8.2 M | - | -5.92 M | -7.44 M | -9.99 M | - | -4.64 M | -4.62 M | -4.81 M | - | -1.37 M | -1.34 M | -3.09 M | - | -919 K | -1.44 M | -2.54 M | - | -1.78 M | -2.07 M | -2.5 M | - | -1.69 M | -2.23 M | -2.96 M | - | -2.22 M | -2.15 M | -2.3 M | - | -1.9 M | -1.48 M | -1.89 M | - | -2.41 M | -1.3 M | -827 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.94 M | -10.6 M | -2.96 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical devices industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Conformis
CFMS
|
-42.2 M | - | - | $ 16.4 M |  USA |
 |
Bruker Corporation
BRKR
|
288 M | $ 64.0 | 7.26 % | $ 9.72 B | USA |
 |
Boston Scientific Corporation
BSX
|
4.98 B | $ 44.68 | 0.06 % | $ 66.1 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
25.2 M | $ 8.7 | 0.06 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
-23.4 M | $ 14.61 | 13.03 % | $ 414 M | USA |
 |
CONMED Corporation
CNMD
|
120 M | $ 45.18 | 3.31 % | $ 1.4 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-13.5 M | $ 4.3 | 1.63 % | $ 268 M | USA |
 |
Eargo
EAR
|
-106 M | - | - | $ 10.2 M | USA |
 |
Delcath Systems
DCTH
|
898 K | $ 16.08 | 0.75 % | $ 576 M | USA |
 |
Medigus Ltd.
MDGS
|
-9.9 M | - | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
-148 M | - | -10.19 % | $ 1.99 M | USA |
 |
Electromed
ELMD
|
14.7 M | $ 27.86 | 1.05 % | $ 230 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-32.8 M | $ 65.58 | 3.69 % | $ 1.94 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
1.42 B | $ 85.73 | 0.32 % | $ 50.1 B | USA |
 |
Nemaura Medical
NMRD
|
-9.15 M | - | -17.8 % | $ 2.74 M |  Britain |
 |
AdaptHealth Corp.
AHCO
|
473 M | $ 5.57 | 0.43 % | $ 753 M | USA |
 |
Helius Medical Technologies
HSDT
|
-244 M | $ 2.9 | 0.69 % | $ 63.9 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
-449 M | $ 15.88 | 2.25 % | $ 1.22 B | USA |
 |
Inogen
INGN
|
-9.55 M | $ 5.23 | 2.75 % | $ 139 M | USA |
 |
InMode Ltd.
INMD
|
86.1 M | $ 14.19 | 0.21 % | $ 917 M | Israel |
 |
Inspire Medical Systems
INSP
|
64.9 M | $ 68.81 | 0.59 % | $ 2.02 B | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
-2.05 M | $ 0.63 | 2.51 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
27.3 M | $ 85.2 | 0.08 % | $ 1.08 B | USA |
 |
Align Technology
ALGN
|
783 M | $ 145.63 | 4.36 % | $ 10.6 B | USA |
|
LENSAR
LNSR
|
-21 M | $ 7.08 | 0.28 % | $ 84.7 M | USA |
 |
Sientra
SIEN
|
-62.4 M | - | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
-56.6 M | - | - | $ 1.07 B | USA |
 |
Medtronic PLC
MDT
|
9.42 B | $ 88.51 | 0.32 % | $ 113 B | USA |
 |
MiMedx Group
MDXG
|
78.8 M | $ 4.71 | 0.1 % | $ 696 M | USA |
 |
Surgalign Holdings
SRGA
|
-76.3 M | - | -32.98 % | $ 1.68 M | USA |
 |
ShockWave Medical
SWAV
|
169 M | - | - | $ 12.3 B | USA |
 |
Myomo
MYO
|
-13.5 M | $ 1.67 | 1.83 % | $ 69.9 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-77 M | $ 0.66 | 0.45 % | $ 42.8 M | Israel |
 |
InspireMD
NSPR
|
426 M | $ 0.7 | 0.37 % | $ 45 M | Israel |
 |
Orthofix Medical
OFIX
|
-4.11 M | $ 9.16 | 0.11 % | $ 363 M |  Curacao |
 |
Outset Medical
OM
|
-62.4 M | $ 3.13 | 1.29 % | $ 47.6 K | USA |
 |
Insulet Corporation
PODD
|
564 M | $ 135.78 | 0.01 % | $ 9.55 B | USA |
 |
Profound Medical Corp.
PROF
|
-40.9 M | $ 5.6 | 1.66 % | $ 169 M | Canada |
 |
Titan Medical
TMDI
|
-31 M | - | -26.32 % | $ 19.6 M | Canada |
 |
Quanterix Corporation
QTRX
|
-110 M | $ 3.18 | 0.63 % | $ 136 M | USA |
 |
Natus Medical Incorporated
NTUS
|
51.9 M | - | 1.94 % | $ 1.05 B | USA |
 |
AVITA Medical
RCEL
|
-40.2 M | $ 11.58 | 5.75 % | $ 323 M |  Australia |
 |
Cardiovascular Systems
CSII
|
-32.1 M | - | 0.15 % | $ 844 M | USA |
 |
Apyx Medical Corporation
APYX
|
-5.79 M | $ 2.83 | 1.37 % | $ 116 M | USA |
 |
Sintx Technologies
SINT
|
-10.4 M | $ 1.87 | 5.06 % | $ 5.19 M | USA |
 |
Accuray Incorporated
ARAY
|
-18.5 M | $ 0.22 | 0.4 % | $ 27 M | USA |
 |
Smith & Nephew plc
SNN
|
1.37 B | $ 26.68 | 0.02 % | $ 23.1 B | Britain |
 |
Inari Medical
NARI
|
-7.14 M | - | - | $ 4.23 B | USA |